TIM-3

TIM-3 Overview

English NameHepatitis A virus cellular receptor 2Approved Drugs0
Drugs in Clinical Trials23Target SynonymT-cell immunoglobulin mucin receptor 3,T-cell membrane protein 3,TIMD3,T-cell immunoglobulin and mucin domain-containing protein 3,HAVcr-2,TIM-3,CD366,HAVCR2,Hepatitis A Virus Cellular Receptor 2,T-Cell Immunoglobulin Mucin Family Member 3,TIMD-3,TIM3,T Cell Immunoglobulin Mucin 3,Kidney Injury Molecule-3,KIM-3,FLJ14428,CD366 Antigen,SPTCL
Highest Development StagePhase 3 Clinical
English NameHepatitis A virus cellular receptor 2
Target SynonymT-cell immunoglobulin mucin receptor 3,T-cell membrane protein 3,TIMD3,T-cell immunoglobulin and mucin domain-containing protein 3,HAVcr-2,TIM-3,CD366,HAVCR2,Hepatitis A Virus Cellular Receptor 2,T-Cell Immunoglobulin Mucin Family Member 3,TIMD-3,TIM3,T Cell Immunoglobulin Mucin 3,Kidney Injury Molecule-3,KIM-3,FLJ14428,CD366 Antigen,SPTCL
Approved Drugs0
Drugs in Clinical Trials23
Highest Development StagePhase 3 Clinical

TIM-3 Product List

  • Product Category

    Protein (11)Antibody (1)

  • Product Status

    Launched (12)

  • Species

    Human (5)Mouse (3)Cynomolgus (2)Canine (1)Rabbit (1)

  • Tag

    His Tag (4)Fc Tag (3)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (1)- (1)

  • Conjugate

    Unconjugated (8)Biotin-labeled (3)PE Labeled (1)

TIM-3 Background

Hepatitis A virus cellular receptor 2 is also known as HAVCR2, FLJ14428, KIM3, TIM3, TIMD3, is a member of the TIM family of immune regulating molecules with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk. CD4-positive T helper lymphocytes can be divided into types 1 (Th1) and 2 (Th2) on the basis of their cytokine secretion patterns. Th1 cells and their associated cytokines are involved in cell-mediated immunity to intracellular pathogens and delayed-type hypersensitivity reactions, whereas Th2 cells are involved in the control of extracellular helminthic infections and the promotion of atopic and allergic diseases. The 2 types of cells also cross-regulate the functions of the other. HAVCR2 is a Th1-specific cell surface protein that regulates macrophage activation and enhances the severity of experimental autoimmune encephalomyelitis in mice. HAVCR2 regulates macrophage activation. Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. May be also involved in T-cell homing. Dysregulation of the HAVCR2-galectin-9 pathway could underlie chronic autoimmune disease states in human, such as multiple sclerosis.

TIM-3 Synonyms

HAVCR2,TIM3,TIMD3,FLJ14428,KIM3

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CobolimabWBP 296A; TSR-022; GSK-4069889Phase 3 ClinicalAnaptysbio IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Diffuse Intrinsic Pontine Glioma; Ependymoma; Fibrolamellar hepatocellular carcinoma; Glioblastoma; Hepatoblastoma; Hodgkin Disease; Liver Neoplasms; Melanoma; Neoplasms; Osteosarcoma; Rhabdomyosarcoma; Uterine Cervical Neoplasms
Details
LB-1410LB-1410Phase 3 ClinicalL&L Biopharma Co LtdLymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
SurzebiclimabBGB-A425Phase 2 ClinicalBeOne Medicines LtdHead and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
LomvastomigRG-7769; RO-7121661; R07121661Phase 2 ClinicalF. Hoffmann-La Roche LtdCarcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Melanoma; Small Cell Lung Carcinoma; Solid tumours
Details
BMS-986258ONO-7807; BMS-986258Phase 2 ClinicalBristol-Myers Squibb Company, Five Prime Therapeutics IncNeoplasms
Details
SabatolimabMBG-453; NVP-MBG453Phase 2 ClinicalNovartis Pharma AgBone Marrow Diseases; Glioblastoma; Hematologic Diseases; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms; Polycythemia Vera; Preleukemia; Primary Myelofibrosis; Thrombocythemia, Essential
Details
SabestomigAZD-7789Phase 2 ClinicalAstraZeneca AgCarcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
S-095018S095018; S-095018Phase 2 ClinicalInstitut De Recherches Internationales Servier, Regeneron Pharmaceuticals Inc, Servier Bio-Innovation LLCCarcinoma, Non-Small-Cell Lung
Details
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University)Phase 2 ClinicalThe Affiliated Hospital Of Xuzhou Medical University, Xuzhou Medical University (Xzmu)Leukemia, Myeloid, Acute
Details
TB-006TB-006; TB006Phase 2 ClinicalTrueBinding IncAlzheimer Disease; Autism Spectrum Disorder; Coronavirus Disease 2019 (COVID-19); Ischemic Stroke; Parkinson Disease
Details
BC-3402BC-3402; BC3402Phase 2 ClinicalWuxi BioCityCarcinoma, Hepatocellular; Hematologic Diseases; Hematologic Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Solid tumours
Details
TQB-2618TQB-2618Phase 2 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdCarcinoma, Hepatocellular; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Lymphoma; Melanoma; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
SHR-1702SHR-1702Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co LtdLeukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours
Details
LY-3321367LY-3321367Phase 1 ClinicalEli Lilly And CompanySolid tumours
Details
TIM-3 checkpoint inhibitor (Bristol-Myers Squibb)Phase 1 ClinicalFive Prime Therapeutics IncNeoplasms
Details
KL-A293KL-A293Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co LtdNeoplasms
Details
NB-002 (Suzhou Luosheng Bio-Pharmaceutical)NB-002 (Suzhou Luosheng Bio-Pharmaceutical); NB-002 (逻晟生物); NB-002Phase 1 ClinicalNeoLogics Bioscience Co LtdNeoplasms; Solid tumours
Details
LPX-TI641LPX-TI-641Phase 1 ClinicalLAPIX Therapeutics IncArthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Demyelinating Diseases; Dermatitis, Atopic; Multiple Sclerosis; Neuromyelitis Optica; Psoriasis
Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals)Bis-5Phase 1 ClinicalL&L Biopharma Co LtdNeoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
LBL-003LBL-003Phase 1 ClinicalNanjing Leadsbiolabs Co LtdNeoplasms
Details
Sym-023Sym-023; Sym023; S95018Phase 1 ClinicalSymphogen A/SLymphoma; Neoplasm Metastasis; Solid tumours
Details
VerzistobartINCAGN-02390; INCAGN-2390Phase 1 ClinicalAgenus Inc, Incyte CorpCarcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma
Details
WBP-3425WBP-3425Phase 1 ClinicalWuxi BioCityColonic Neoplasms; Solid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland